Gfh375 (VS-7375) subgroup analysis for 2L pancreatic cancer is available and ORR is 58% @ 600 dose with 100% DCR (ASCO25) #AACR26

Back to meeting Original

Back to meeting

CrozrX· @CrozrX · X·2026-04-20 04:16· 2026-04-20Score60

VS-7375

Reading

KRAS / RAS targeting: from platform to Phase 3

The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.

zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.

Body

Gfh375 (VS-7375) subgroup analysis for 2L pancreatic cancer is available and ORR is 58% @ 600 dose with 100% DCR (ASCO25) #AACR26

Heat 4 · 4 likes · 0 replies · 0 reposts

Conference abstracts

7100NCT06500676 NCT07020221matched by 代号 VS-7375

VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents

Silvia Coma, Ian Smith, Cristina Caffarra Malvezzi, Clint A. Stalnecker, Emilia Berardelli, Enrico Patrucco, Fusheng Zhou, Channing Der, Chiara Ambrogio, David G. DeNardo, Jonathan A. Pachter

Read the abstract →

LB183matched by 代号 VS-7375

Strong durable tumor regressions with the KRASG12D ON/OFF inhibitor VS-7375 in combination with PRMT5 inhibition in MTAP-deleted/KRASG12D-mutant pancreatic cancer

Ryan D. Mouery, Kristina Drizyte-Miller, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der

Read the abstract →

LB197matched by 代号 VS-7375

VS-7375, a non-covalent dual ON/OFF KRASG12D inhibitor, displays superior activity to ON-only KRASG12D inhibitors in preclinical models of pancreatic cancer

Brandon L. Mouery, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der

Read the abstract →

Source: CrozrX · x.com